Zenlabs Ethica reported a significant expansion in revenue for the quarter ended June 30, 2026, but faced pressure on its bottom line, resulting in a widened net loss.

The pharmaceutical trading firm logged revenue from operations at ₹1,417.7 crore, marking a 23.5% increase from ₹1,147.7 crore in Q1FY25. This represents a strong sequential recovery as well, rising 34% from ₹1,058.4 crore in the immediately preceding quarter (Q4FY25).

Despite the robust topline performance, profitability deteriorated sharply. The company recorded a net loss of ₹57.1 crore for the quarter, a stark contrast to the net profit of ₹3.3 crore reported in Q1FY25. In the previous quarter (Q4FY25), the company had posted a marginal net profit of ₹0.1 crore.

Operational Expenses and Margin Pressure

Total expenses surged to ₹1,473.3 crore in Q1FY26, up from ₹1,143.7 crore in the same period last year. The rise in costs outpaced revenue growth, leading to a pre-tax loss of ₹55.6 crore.

Key expense drivers included:

• Purchase of stock-in-trade: ₹877.5 crore (down from ₹1,012.3 crore YoY)
• Increase in stock-in-trade: ₹475.9 crore (compared to a decrease of ₹183.0 crore YoY)
• Employee benefit expenses: ₹45.2 crore (down significantly from ₹104.1 crore YoY)
• Other expenditure: ₹48.1 crore (down from ₹160.1 crore YoY)

The substantial increase in inventory levels (stock-in-trade) appears to be a primary factor contributing to the higher total expenditure and the resulting loss, despite lower purchase costs and employee benefits compared to the prior year.

What the Numbers Show

The divergence between revenue growth and profitability is driven by working capital dynamics rather than operational inefficiencies in core costs. While revenue grew 23.5% YoY, employee benefits and other expenditures fell significantly. However, the ₹475.9 crore increase in stock-in-trade in Q1FY26, compared to a decrease of ₹183.0 crore in Q1FY25, indicates a heavy build-up of inventory. This inventory accumulation, treated as an expense in the cost of goods sold calculation, directly impacted the bottom line, turning a profitable quarter into a loss-making one despite lower direct purchase and operational costs.

Auditor Review and Compliance

The unaudited financial results were reviewed by N Kumar Chhabra and Co., Chartered Accountants, who expressed no material misstatements. The Board of Directors approved the results on August 12, 2026, in compliance with SEBI LODR regulations. The company operates as a single segment entity engaged in pharmaceutical formulation trading.

Zenlabs Ethica has appointed Mr. Sanjay Dhir as its Chief Financial Officer (CFO) effective July 21, 2026. The Board of Directors approved the appointment to fulfil the requirements of Section 203 of the Companies Act, 2013, read with Rule 8 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The company informed BSE Limited of this regulatory development under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Mr. Sanjay Dhir brings extensive experience in accounting, finance, and compliance, with a proven ability to manage complex financial operations and strengthen governance frameworks. His expertise spans financial reporting, accounting controls, budgeting, and regulatory compliance, ensuring the organization's financial practices are efficient, transparent, and aligned with statutory and accounting requirements.

The appointment is effective immediately from July 21, 2026. The term of appointment was specified as not applicable in the regulatory disclosure. Mr. Dhir has provided his consent to act as CFO and confirmed his eligibility for the position in accordance with applicable laws and company policies.

Appointment Details